-
1 Comment
Cochlear Limited is currently in a long term uptrend where the price is trading 14.0% above its 200 day moving average.
From a valuation standpoint, the stock is 96.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.4.
Cochlear Limited's total revenue sank by 1.7% to $743M since the same quarter in the previous year.
Its net income has increased by 49.8% to $236M since the same quarter in the previous year.
Finally, its free cash flow grew by 1119.6% to $34M since the same quarter in the previous year.
Based on the above factors, Cochlear Limited gets an overall score of 4/5.
Exchange | AU |
---|---|
CurrencyCode | AUD |
ISIN | AU000000COH5 |
Sector | Healthcare |
Industry | Medical Devices |
Market Cap | 18B |
---|---|
Target Price | 286.828 |
Dividend Yield | 1.6% |
Beta | 0.38 |
PE Ratio | 48.76 |
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for COH.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025